Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Long Term Incentive Plan

10 May 2016 16:30

RNS Number : 8338X
Allied Minds PLC
10 May 2016
 

 

 

10 MAY 2016

 

Allied Minds plc (the "Company" or the "Group")

 

Long Term Incentive Plan

 

Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, announces that on 09 May 2016 it made conditional awards of 1,499,247 ordinary shares of one pence each ("Ordinary Shares") to certain directors, other persons discharging managerial responsibilities ("PDMRs") and certain other employees under its Long Term Incentive Plan (the "LTIP").

 

Conditional awards in the form of restricted share units have been made to the directors and PDMRs totalling 1,147,290 Ordinary Shares as follows:

 

Director/PDMR

Maximum number of Ordinary Shares conditionally awarded in respect of 2016 LTIP

Maximum number of conditionally awarded Ordinary Shares outstanding at the date of this announcement (including 2016 LTIP)

Chris Silva

238,470

1,763,441

Marc Eichenberger

139,902

1,044,264

Joseph Pignato1

501,636

501,636

Michael Turner

104,186

1,004,464

Omar Amirana

57,418

377,664

John Serafini

49,083

296,519

Peter Dolan (Non-Executive)

15,435

23,605

Richard Davis (Non-Executive)

10,290

15,736

Jeffrey Rohr (Non-Executive)

10,290

15,736

Kevin Sharer (Non-Executive)

10,290

15,736

Jill Smith (Non-Executive)

10,290

10,290

_______________

1 The grant to Joseph Pignato is composed of two parts. Mr. Pignato's 2016 annual grant is 115,762 units and is subject to ordinary vesting conditions through 31 December 2018. Mr. Pignato, who joined the Company in August 2015 as its Chief Financial Officer, was also awarded a new hire grant of 385,874 units under the terms of the LTIP, which was in part compensation for the loss of awards from previous employment. Such grant is also subject to ordinary vesting conditions through 31 December 2018; provided, however, that such new hire grant shall be paid out after the three years ending 31 December 2018 (50%), 2019 (25%) and 2020 (25%).

 

The number of Ordinary Shares stated is the maximum number that could be issued to each director or PDMR upon full satisfaction of the performance conditions attaching to the awards. The awards granted to the non-executive directors are not subject to performance conditions, but instead vest in three equal tranches on the first, second and third anniversaries of grant, subject to the non-executive director continuing to provide services to the Group on the relevant vesting date.

 

In addition to the above, awards in the form of restricted share units over a total of 351,957 Ordinary Shares were made to certain other of the Group's employees pursuant to the 2016 LTIP.

 

The performance conditions attaching to the 2016 awards (other than the non-executive director awards) are based on the achievement of performance metrics measured as follows: 100% of each award will be subject to performance conditions based on the Company's relative total shareholder return (rTSR) performance in respect the period from 01 January 2016 through 31 December 2018. The Company's rTSR will be measured relative to the FTSE 250, the S&P 500, and a peer group of four publicly-traded companies. The Group's Remuneration Policy and Annual Remuneration Report were approved by the Company's shareholders at its Annual General Meeting held on 28 May 2015, and will be again be subject to approval at the Annual General Meeting to be held on 26 May 2016.

 

The awards will vest, to the extent that the performance conditions have been satisfied, on the date following 31 December 2018 on which the extent to which the performance conditions have been satisfied is determined, and the Ordinary Shares will be issued as soon as practicable after such date.

 

As at the date of this announcement, a total of 6,387,170 Ordinary Shares have been conditionally awarded to directors, PDMRs and employees of the Company pursuant to the LTIP and remain subject to performance conditions (other than the non-executive director awards). The Company currently has 215,637,363 Ordinary Shares in issue.

 

About Allied Minds

 

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialisation company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

 

For more information, please contact:

Allied Minds plc

+1 617 419 1800

Chris Silva, Chief Executive Officer

www.alliedminds.com

 

 

Citigate Dewe Rogerson

+44 20 7638 9571

Patrick Donovan/Rob Newman

alliedminds@citigatedr.co.uk

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBUGDULGBBGLG
Date   Source Headline
16th Jul 20217:00 amRNSTransaction in Own Shares
13th Jul 20217:00 amRNSTransaction in Own Shares
7th Jul 20217:00 amRNSTransaction in Own Shares
5th Jul 20217:00 amRNSTransaction in Own Shares
2nd Jul 20217:00 amRNSTransaction in Own Shares
1st Jul 20217:00 amRNSTransaction in Own Shares
30th Jun 20217:00 amRNSTransaction in Own Shares
29th Jun 20217:00 amRNSTransaction in Own Shares
28th Jun 20217:00 amRNSTransaction in own shares
25th Jun 20217:00 amRNSTransaction in own shares
24th Jun 20217:00 amRNSTransaction in own shares
23rd Jun 20217:00 amRNSPortfolio company update and share buyback
16th Jun 20214:41 pmRNSSecond Price Monitoring Extn
16th Jun 20214:36 pmRNSPrice Monitoring Extension
3rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
3rd Jun 20214:35 pmRNSPrice Monitoring Extension
1st Jun 20217:00 amRNSOcuTerra Therapeutics Series B Second Close
24th May 20214:41 pmRNSSecond Price Monitoring Extn
24th May 20214:36 pmRNSPrice Monitoring Extension
18th May 20214:40 pmRNSSecond Price Monitoring Extn
18th May 20214:35 pmRNSPrice Monitoring Extension
12th May 20215:28 pmRNSResult of AGM
11th May 20217:00 amRNSBlock listing Interim Review
11th May 20217:00 amRNSBlock listing Interim Review
11th May 20217:00 amRNSBlock listing Interim Review
28th Apr 20217:00 amRNSOcuTerra Therapeutics Raises Series B Financing
15th Apr 20217:00 amRNSBlock Listing Application
13th Apr 20217:00 amRNSOrbital Sidekick Closes $16m Series A Financing
9th Apr 20217:00 amRNSCapital Markets Day
6th Apr 20217:00 amRNSNotice of AGM
1st Apr 20215:34 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSAnnual results release
29th Mar 20214:28 pmRNSHolding(s) in Company
22nd Mar 20217:00 amRNSNotice of results - update
18th Mar 20214:41 pmRNSSecond Price Monitoring Extn
18th Mar 20214:36 pmRNSPrice Monitoring Extension
11th Mar 20214:36 pmRNSPrice Monitoring Extension
1st Mar 20219:00 amRNSNotice of Results
23rd Feb 20217:00 amRNSBridgeComm Advances Development of MOCA Technology
2nd Feb 20219:33 amRNSDirector/PDMR Shareholding
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSDirectorate Change
8th Jan 20214:36 pmRNSPrice Monitoring Extension
4th Jan 20215:15 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSStrategic update
24th Dec 20207:00 amRNSOrbital Sidekick Series A Financing
21st Dec 20203:25 pmRNSFederated Wireless partners with TESSCO
1st Dec 20203:35 pmRNSTotal Voting Rights
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNSShareholder engagement update on 2020 AGM vote

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.